By In recent trading activity, OrbiMed Advisors LLC has reported selling shares of Passage BIO, Inc. (NASDAQ:PASG), a biotechnology company specializing in biological products. The transactions, which took place over a series of three days, resulted in the sale of a significant portion of OrbiMed’s holdings in the company.
The sales commenced on September 16, 2024, with OrbiMed Advisors offloading 63,100 shares at an average price of $0.74 per share. The selling continued on September 17, with an additional 111,400 shares sold at an average price of $0.73. On September 18, a further 25,631 shares were sold, also at the average price of $0.73. According to the footnotes provided in the SEC filing, these prices represent a weighted average, with the actual sale prices ranging from a low of $0.73 to a high of $0.78 per share.
The total value of the shares sold by OrbiMed Advisors during this period amounted to approximately $146,726. These transactions have adjusted OrbiMed’s ownership stake in Passage BIO, Inc., with shares owned following the transactions totaling 7,833,869.
OrbiMed Capital GP VII LLC, which is associated with OrbiMed Advisors and holds shares of Passage Bio indirectly, is also mentioned in the filing. Both entities have indicated, through footnotes in the report, that they may be deemed to have voting and investment power over the shares held. However, they disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest, if any.
Investors and followers of Passage BIO, Inc. will take note of these transactions as they assess the investment landscape and consider the implications of such sales by a significant shareholder.
In other recent news, Passage Bio, Inc. has been making significant strides in its operations and strategic efforts. The company has reported an estimated impairment cost between $3.5 million and $5.5 million, related to its recent sublease agreement and corporate restructuring efforts. Passage Bio has also appointed Thomas Kassberg, a seasoned biotech veteran, as a Class I director and member of the Audit Committee, a move expected to strengthen its governance and strategic capabilities.
In the business arena, Passage Bio has out-licensed treatments for GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy to GEMMA Biotherapeutics, Inc. This deal includes an upfront payment of $10 million and potential additional payments tied to business milestones. Furthermore, the U.S. Food and Drug Administration has approved the company’s gene therapy treatment, PBFT02, for evaluation in frontotemporal dementia patients with C9orf72 gene mutations.
However, the company is currently evaluating options to regain compliance with Nasdaq’s listing requirements, following a potential delisting notice due to its share price falling below the minimum bid price requirement. On the research front, Canaccord Genuity has maintained a Buy rating for Passage Bio stock, highlighting positive interim data from the upliFT-D Phase 1/2 study. These are recent developments in Passage Bio’s ongoing efforts to address the unmet needs of the patient community.
InvestingPro Insights
As investors digest the recent sell-off by OrbiMed Advisors in Passage BIO, Inc. (NASDAQ:PASG), it’s essential to consider the broader financial health and market sentiment surrounding the company. According to InvestingPro data, Passage BIO has a market capitalization of approximately $45.09 million, which reflects its current valuation in the market.
One notable InvestingPro Tip for Passage BIO is that the company holds more cash than debt on its balance sheet, which can be a sign of financial stability in the biotech industry where cash flow is critical for sustained research and development. However, it is also important to note that analysts have expressed concerns about the company’s cash burn rate, indicating that Passage BIO is quickly using its available cash resources.
InvestingPro Data also shows that the stock has experienced a substantial decline over recent periods, with a 6-month price total return of -51.99% and a 1-week price total return of -8.49%. This could suggest that market sentiment has been bearish, which may have influenced OrbiMed’s decision to reduce its position in the company.
For those looking for more in-depth analysis, there are additional InvestingPro Tips available, which include insights on the company’s gross profit margins, profitability expectations, and valuation in terms of free cash flow yield. For example, Passage BIO is not expected to be profitable this year, and it suffers from weak gross profit margins. These factors might be crucial for investors to consider when evaluating the company’s future prospects.
Interested readers can find further expert analysis and tips by visiting InvestingPro’s dedicated page for Passage BIO at https://www.investing.com/pro/PASG, where a total of 10 InvestingPro Tips are available to help guide investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
